US · cnbc.com

See the biopharma stock Goldman Sachs says to buy

Exclusively for CNBC Pro Subscribers - This stock is poised to rally nearly 40%

This email was sent

Is this your brand on Milled? Claim it.

Exclusively for CNBC Pro Subscribers - This stock is poised to rally nearly 40%
CNBC PRO
The Wall Street Bull (The Charging Bull) is seen during Covid-19 pandemic in Lower Manhattan, New York City, United States on May 26, 2020.

Morsa Images | DigitalVision | Getty Images

Goldman Sachs says it’s time for investors to put their money in this stock as its shares can rally nearly 40% with success trials of its new medicine.

 

Although shares for this company have rallied more than 320% since the release of the trial data, Goldman Sachs' analyst Corinne Jenkins sees further upside to the stock should this medicine continue to succeed in clinical trials.

 

Subscribe to CNBC Pro to see which stock Goldman Sachs says could rally and gain another 38% from Friday's close.

CNBC Pro

Like getting these emails?  Subscribe to CNBC Pro today and get access to unlimited Pro articles, access to Pro live events, stock tips, and money-making investment ideas.

CNBC PRO logo
Facebook Twitter Instagram YouTube
Download the iOS App
Download the Android App

© 2022 CNBC LLC. All rights reserved. A property of NBCUniversal.

 

900 Sylvan Avenue, Englewood Cliffs, NJ 07632

 

Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis.

 

Data also provided by THOMSON REUTERS

Recent emails from CNBC See more